09-12-2020
STALICLA will present new data from the biological characterization of a novel DEPI-identified endophenotype within Autism Spectrum Disorder (ASD): ASD Phenotype 1 (ASD-Phen1) at The BRAIN Foundation Synchrony 2020 conference Dec. 12th 2020
03-12-2020
STALICLA is now enrolling patients with ASD Phenotype 1 in the first interventional trial with STP1 in this biologically-defined subpopulation (NCT04644003). STALICLA is also conducting two observational studies (NCT04600882 and NCT04273087) to identify new subgroups of patients within the autism spectrum.
25-11-2020
Tackling the challenges of precision medicine in Neuropsychiatry
20-11-2020
Scaling Tech into Successful Companies
30-09-2020
STP1 is the first precision treatment to enter the clinic for a biologically-defined subgroup of patients with autism spectrum disorder.
